Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EoceneEOCN +21.05%29 EV-to-EBITDA is 0.62 as of Sep. 11, 2026, which is 67% below its 10-year median of 1.89. GuruFocus rates EOCN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 403 Biotechnology companies, Eocene ranks better than 84.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eocene's enterprise value is $-6.19 Mil.
Eocene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-9.96 Mil. Therefore, Eocene's EV-to-EBITDA for today is 0.62.
The historical rank and industry rank for Eocene's EV-to-EBITDA or its related term are showing as below:
EOCN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.38 Med: 1.89 Max: 6.01
Current: 0.62
During the past 13 years, the highest EV-to-EBITDA of Eocene was 6.01. The lowest was -19.38. And the median was 1.89.
EOCN's EV-to-EBITDA is ranked better than 84.62% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs EOCN: 0.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-11), Eocene's stock price is $4.09.
Eocene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-15.180. Therefore, Eocene's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eocene's share price for today is $4.09.
Eocene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Eocene's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eocene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eocene EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eocene's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eocene's EV-to-EBITDA falls into.
Eocene's current Enterprise Value is $-6.19 Mil.
Eocene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eocene (EOCN) has a EV-to-EBITDA of 0.62 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eocene. This is 67% below median its historical median of 1.89. According to the industry distribution chart, Eocene ranks #62 out of 403 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Eocene's EV-to-EBITDA too high?
Eocene's current EV-to-EBITDA of 0.62 is 67% below median its 10-year median of 1.89. The Biotechnology industry median EV-to-EBITDA is 13.21. Eocene's value of 0.62 is 95.3% below this industry median. Based on the distribution chart, Eocene ranks #62 out of 403 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Eocene has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Eocene's EV-to-EBITDA compare to ELAB and SILO?
According to the Biotechnology industry distribution chart, Eocene ranks #62 out of 403 companies for EV-to-EBITDA. This places Eocene in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.21. Eocene's value of 0.62 is 95.3% below this benchmark. While the company's 10-year median is 1.89 vs. the industry median of 13.21, Eocene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eocene's current EV-to-EBITDA of 0.62 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eocene. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eocene's current EV-to-EBITDA is 0.62, which is 67% below median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eocene stock overvalued right now?
Eocene (EOCN) has a current EV-to-EBITDA of 0.62. The current EV-to-EBITDA is 0.62, which is 67% below median its 10-year median of 1.89 and 95.3% below the Biotechnology industry median of 13.21. Eocene's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eocene (EOCN), the current EV-to-EBITDA is 0.62 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
29GF Score
Get the complete analysis for EOCN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOCN has been successfully added to your 
